{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-029606","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.055997+00:00","generated_at":"2026-06-21T20:03:28.647559+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avalo Therapeutics sells AVTX-501 milestones and AVTX-007 royalties to ES Therapeutics for $5M","bullets":["Closed sale to ES Therapeutics (Armistice affiliate) of rights to milestones from Janssen (AVTX-501) and royalty payments from Apollo (AVTX-007).","Waived all rights under AVTX-611 license agreement with ES and Armistice.","Received $5.0M cash payment upon closing on November 10, 2022.","Board approved under related party policy; Armistice is a significant stockholder."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-029606","json":"https://secwatch.observer/filing/0001628280-22-029606.json","markdown":"https://secwatch.observer/filing/0001628280-22-029606.md","text":"https://secwatch.observer/filing/0001628280-22-029606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022029606/0001628280-22-029606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022029606/avtx-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:03:28.647559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e4c73fe60c54dca5fb5042ead39f64fd725bb3b","claim":"Avalo Therapeutics, Inc. completed a disposition involving ES Therapeutics, LLC for $5.0 million (closed 2022-11-10).","evidence_excerpt":"The transaction closed on November 10, 2022 and the Company has received the $5.0 million payment from ES.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828022029606/0001628280-22-029606-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"ES Therapeutics, LLC"},{"label":"Consideration","value":"$5.0 million"},{"label":"Closing","value":"2022-11-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}